
Hosts Mitsuaki Sawano, MD, Kentaro Ejiri, MD, and Hiroyuki Sato, MD welcome Tomoya Iwawaki, MD and Satoshi Yanagisawa, MD to discuss their JACC: Clinical Electrophysiology study, “Optimal Timing for Oral Anticoagulant Discontinuation and Prognosis After Successful Catheter Ablation for Atrial Fibrillation.” Using data from 2,448 patients undergoing first-time AF ablation, the investigators performed 537 sequential landmark analyses to identify when the balance between thromboembolic protection and bleeding risk most favors oral anticoagulant discontinuation. The episode explores how stroke and bleeding risks evolve after ablation, the concept of reverse net clinical benefit, why the first several months after discontinuation may be particularly vulnerable, and whether a data-driven approach can help guide one of the most common questions in contemporary AF management: when is it truly safe to stop anticoagulation after a successful ablation?
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

PACs: Benign Bystanders or AF in Disguise? | JACC Baran

Cancer VTE + DOAC: Who Will Bleed? | JACC Baran

HFpEF Without Obesity: What Coronary Microcirculation Tells Us | JACC Baran

What Autopsy Reveals About MINOCA and Sudden Cardiac Death | JACC Baran
Free AI-powered recaps of JACC Global and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.